Results 201 to 210 of about 69,111 (289)

Splenomegaly, hypersplenism, and hereditary disorders with splenomegaly

, 2013
Neal J. Weinreb, Barry E. Rosenbloom
openalex   +2 more sources

Hepatomegaly , Splenomegaly and lymphadenopathy in Iraqi patients with Systemic Lupus Erythematosus...

, 2020
Naser Husain Sabr, Khalaf Anber Obaid, Adnan Hiyal Nisan   +2 more
openalex   +1 more source

Partial Nuclear Extrusion in Chronic Lymphocytic Leukemia Observed to Be an In Vitro Artefact

American Journal of Hematology, Volume 101, Issue 2, Page 337-338, February 2026.
Rima Chatila, Guillaume Beziat, Laure Pirovano, Clément Bouyssie, Jean‐Baptiste Rieu, Barbara J. Bain   +5 more
wiley   +1 more source

Low ICU Admission and Excellent Outcomes in MIS‐C: A Swedish Study From an Open Society

Acta Paediatrica, Volume 115, Issue 2, Page 335-344, February 2026.
ABSTRACT Aim During the COVID‐19 pandemic, Sweden chose a more open public health approach. A general concern was that this approach would affect the population negatively. We describe the Swedish national MIS‐C cohort and risk factors for severe disease defined as admission to the intensive care unit and cardiogenic shock.
Petra Król, Maria Altman, Stefan Berg, Lillemor Berntson, Petter Brodin, Anders Fasth, Robin Kahn, Jenny Lingman Framme, Maria Mossberg, Charlotta Nordenhäll, Karin Palmblad, André Rudolph, Eva Säve‐Söderbergh, AnnaCarin Horne   +13 more
wiley   +1 more source

Quantitative assessment of innate myeloid cells in myelofibrosis: insights into myeloid and plasmacytoid dendritic cell depletion and disease progression. [PDF]

Ann Hematol
Silva NAC, Guirao FP, Barbosa MCR, Bernal DAO, Vassalli LC, Sandes AF.   +5 more
europepmc   +1 more source

Non‐Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 4, Page 494-506, February 2026.
In a multi‐centre study of obeticholic acid in primary biliary cholangitis, 45% discontinued the drug over 4 years, with 11% moving to combination therapy (fibrates). Of those continuing, response rates increased from 37% (1 year) to 55% (4 years). Non‐response at 12 months and cirrhosis were independent predictors of liver‐related events.
Nadir Abbas, Rachel Smith, Ellina Lytvyak, Miki Scaravaglio, Neil Halliday, Amal Almahroos, Nadia Eden, Diane Lloyd‐Madden, Sanchit Sharma, James Ferguson, Jessica K. Dyson, Douglas Thorburn, David Jones, Aldo J. Montano‐Loza, Marco Carbone, Pietro Invernizzi, George Mells, Emma L. Culver, Palak J. Trivedi   +18 more
wiley   +1 more source

Cytopenias and Large Splenomegaly are Main Drivers of Poor Outcome after Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis

Francesca Palandri, Massimo Breccia, Erika Morsia, Elena Maria Elli, Giulia Benevolo, Mario Tiribelli, Eloise Beggiato, Mirko Farina, Giovanni Caocci, Novella Pugliese, Alessia Tieghi, Monica Crugnola, Gianni Binotto, Francesco Cavazzini, Elisabetta Abruzzese, Alessandro Isidori, Alessandra Dedola, Alessandra Iurlo, Roberto M. Lemoli, Daniela Cilloni, Monica Bocchia, Florian H. Heidel, Massimiliano Bonifacio, Giuseppe A. Palumbo, Filippo Branzanti   +24 more
openalex   +1 more source

Potentiation of graft-versus-host reaction-induced splenomegaly by a single electroacupuncture treatment in F1 hybrid mice

, 1994
Takako Kasahara, K. Oguchi, T Hisamitsu
openalex   +1 more source

RNA Analysis Uncovers Pathogenic PARN Variant in Dyskeratosis Congenita

Clinical Genetics, Volume 109, Issue 2, Page 346-351, February 2026.
Using WGS and RNA analysis, we identified a branch point‐disrupting variant in the PARN gene and elucidated its pathogenic molecular mechanism in a child with atypical dyskeratosis congenita presentation. ABSTRACT Dyskeratosis congenita (DC) is a rare genetic disorder caused by impaired telomere maintenance, leading to diverse clinical manifestations ...
Daria Akimova, Natalia Semenova, Tatiana Cherevatova, Mikhail Skoblov   +3 more
wiley   +1 more source